Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database

Published:2021-06-09 Issue:6 Volume:43 Page:1508-1515
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Guo Mingxing,Thai Sydney,Zhou Junwen,Wei Jingkai,Zhao Ying,Xu Wanyi,Wang Tiansheng,Cui Xiangli

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy

Link

https://link.springer.com/content/pdf/10.1007/s11096-021-01273-8.pdf

Reference24 articles.

1. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

2. Enea I, Roncon L, Gulizia MM, Azzarito M, Becattini C, Bongarzoni A, et al. ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention. Eur Heart J Suppl. 2017;19(Suppl D):D293–308.

3. January CT, Wann LS, Calkins H, Field ME, Chen LY, Furie KL, et al. 2019 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–51.

4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

5. Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database;Expert Opinion on Drug Safety;2024-06-18

2. An explorative analysis of pharmacovigilance data of oxytocin and its analogue carbetocin, with a focus on haemodynamic adverse effects;International Journal of Clinical Pharmacy;2023-05-10

3. Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database;Scientific Reports;2023-03-18

4. Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System;Frontiers in Pharmacology;2022-01-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3